Amanat Acquisition Prices IPO at $10.00 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Amanat Acquisition announced the pricing of its initial public offering of 7.5M shares at an offering price of $10.00 per share. The shares are expected to trade on the Nasdaq under the ticker symbol "AMAN" beginning today. Amanat is a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company intends to focus on opportunities in healthcare or healthcare-related industries. Leerink Partners is acting as sole bookrunning manager.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMAN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMAN
Wall Street analysts forecast AMAN stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 10.130
Low
Averages
High
Current: 10.130
Low
Averages
High
No data
About AMAN
Amanat Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company is not engaged in any operations and is not generating revenue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three IPOs and Seven SPACs Priced This Week
- Successful Pricing of Lincoln Financial: Lincoln Financial (LCLN) priced at $421 million, achieving a market cap of $2.2 billion, indicating strong demand in the private capital markets despite geopolitical and private credit concerns affecting peers.
- Direct Listing of AMASS Brands: Beverage company AMASS Brands (AMSS) completed its direct listing on Nasdaq, yet its stock fell 52% from the $8.98 price of its last funding round, reflecting market caution towards its premium beverage platform.
- Conexeu Sciences Surge: Medical device developer Conexeu Sciences (CNXU) completed a direct listing on Nasdaq, with its stock soaring 260% from the $4.00 price of its most recent private placement, showcasing investor enthusiasm for its unique regenerative medical technology.
- SPACs Pricing Overview: Seven SPACs priced this week, with Oceanhawk Acquisition (OHACU) raising $160 million and Aperture AC (APURU) raising $90 million, demonstrating ongoing market interest in blank check companies despite an uncertain overall market environment.
See More
Amanat Acquisition Corp. Prices IPO at $10 per Share
- IPO Pricing Announcement: Amanat Acquisition Corp. has priced its initial public offering at $10 per share for 7.5 million Class A ordinary shares, successfully raising $75 million to fund future merger opportunities.
- Underwriter Option: The company has granted the underwriter a 45-day option to purchase up to an additional 1.125 million Class A ordinary shares to cover any over-allotments, enhancing market flexibility and potential capital influx.
- Exchange Listing Plans: The Class A ordinary shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol 'AMAN' on May 19, marking a significant milestone for the company as it enters the public market.
- Industry Focus: This special purpose acquisition company intends to concentrate on merger opportunities within the healthcare or healthcare-related sectors, reflecting its strategic emphasis on the rapidly growing healthcare market.
See More
Amanat Acquisition Raises $75 Million for Life Sciences SPAC
- Funding Details: Amanat Acquisition successfully raised $75 million by offering 7.5 million common shares at $10 each, reflecting ongoing market interest and investment enthusiasm in the life sciences sector.
- Transaction Structure: Unlike most SPACs, Amanat Acquisition opted to sell common shares instead of units containing warrants or rights, a strategy that may attract a broader investor base and simplify the transaction structure.
- Management Team Background: The company is led by biotech executive Sandeep Kulkarni, who serves as CEO of Zura Bio and was previously the co-founder of Tourmaline Bio, bringing extensive industry experience that enhances investor confidence.
- Market Focus: Amanat Acquisition plans to target the healthcare industry, particularly the biotechnology and life sciences sectors, aiming to capitalize on the current demand for late-stage private biotech companies exploring public offerings.
See More
Amanat Acquisition Corp Prices Initial Public Offering at $10 per Share
- IPO Pricing: Amanat Acquisition Corp has priced its initial public offering at $10.00 per share for 7,500,000 Class A ordinary shares, with trading expected to commence on May 20, 2026, indicating strong market confidence in its future business combinations.
- Industry Focus: The company intends to target opportunities in the healthcare and healthcare-related sectors for mergers and acquisitions, leveraging the management team's expertise to create long-term shareholder value, which highlights its strategic direction.
- Underwriting Arrangement: Leerink Partners is acting as the sole bookrunning manager for the IPO and has been granted a 45-day option to purchase up to 1,125,000 additional Class A ordinary shares, demonstrating flexibility in responding to market demand.
- Registration Statement Effective: The U.S. Securities and Exchange Commission declared the registration statement related to the IPO effective on May 18, 2026, ensuring the legality of the company's fundraising efforts within compliance frameworks, thereby enhancing investor confidence.
See More
Three IPOs and Seven SPACs Priced This Week
- Successful Pricing of Lincoln Financial: Lincoln Financial (LCLN) priced at $421 million, achieving a market cap of $2.2 billion, indicating strong demand in the private capital markets despite geopolitical and private credit concerns affecting peers.
- Direct Listing of AMASS Brands: Beverage company AMASS Brands (AMSS) completed its direct listing on Nasdaq, yet its stock fell 52% from the $8.98 price of its last funding round, reflecting market caution towards its premium beverage platform.
- Conexeu Sciences Surge: Medical device developer Conexeu Sciences (CNXU) completed a direct listing on Nasdaq, with its stock soaring 260% from the $4.00 price of its most recent private placement, showcasing investor enthusiasm for its unique regenerative medical technology.
- SPACs Pricing Overview: Seven SPACs priced this week, with Oceanhawk Acquisition (OHACU) raising $160 million and Aperture AC (APURU) raising $90 million, demonstrating ongoing market interest in blank check companies despite an uncertain overall market environment.
See More
Amanat Acquisition Corp. Prices IPO at $10 per Share
- IPO Pricing Announcement: Amanat Acquisition Corp. has priced its initial public offering at $10 per share for 7.5 million Class A ordinary shares, successfully raising $75 million to fund future merger opportunities.
- Underwriter Option: The company has granted the underwriter a 45-day option to purchase up to an additional 1.125 million Class A ordinary shares to cover any over-allotments, enhancing market flexibility and potential capital influx.
- Exchange Listing Plans: The Class A ordinary shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol 'AMAN' on May 19, marking a significant milestone for the company as it enters the public market.
- Industry Focus: This special purpose acquisition company intends to concentrate on merger opportunities within the healthcare or healthcare-related sectors, reflecting its strategic emphasis on the rapidly growing healthcare market.
See More
Amanat Acquisition Raises $75 Million for Life Sciences SPAC
- Funding Details: Amanat Acquisition successfully raised $75 million by offering 7.5 million common shares at $10 each, reflecting ongoing market interest and investment enthusiasm in the life sciences sector.
- Transaction Structure: Unlike most SPACs, Amanat Acquisition opted to sell common shares instead of units containing warrants or rights, a strategy that may attract a broader investor base and simplify the transaction structure.
- Management Team Background: The company is led by biotech executive Sandeep Kulkarni, who serves as CEO of Zura Bio and was previously the co-founder of Tourmaline Bio, bringing extensive industry experience that enhances investor confidence.
- Market Focus: Amanat Acquisition plans to target the healthcare industry, particularly the biotechnology and life sciences sectors, aiming to capitalize on the current demand for late-stage private biotech companies exploring public offerings.
See More
Amanat Acquisition Corp Prices Initial Public Offering at $10 per Share
- IPO Pricing: Amanat Acquisition Corp has priced its initial public offering at $10.00 per share for 7,500,000 Class A ordinary shares, with trading expected to commence on May 20, 2026, indicating strong market confidence in its future business combinations.
- Industry Focus: The company intends to target opportunities in the healthcare and healthcare-related sectors for mergers and acquisitions, leveraging the management team's expertise to create long-term shareholder value, which highlights its strategic direction.
- Underwriting Arrangement: Leerink Partners is acting as the sole bookrunning manager for the IPO and has been granted a 45-day option to purchase up to 1,125,000 additional Class A ordinary shares, demonstrating flexibility in responding to market demand.
- Registration Statement Effective: The U.S. Securities and Exchange Commission declared the registration statement related to the IPO effective on May 18, 2026, ensuring the legality of the company's fundraising efforts within compliance frameworks, thereby enhancing investor confidence.
See More
